## Zero-Shot 3D Drug Design by Sketching and Generating

#### Siyu Long<sup>1</sup>, Yi Zhou<sup>2</sup>, Xinyu Dai<sup>1\*</sup>, Hao Zhou<sup>3\*</sup> 1 National Key Laboratory for Novel Software Technology, Nanjing University

2 ByteDance AI Lab

3 Institute for AI Industry Research, Tsinghua University







## Outline

- Overview
- Background
- Related Work
- Motivation
- Method (DESERT)
- Experiment
- Conclusion

## Overview

- We develop a novel shape-based method for de-novo 3D drug design
- It does not need training data from the wet lab
- It achieves a new SOTA at a fast speed



# Background

- Drug Design
  - Provide molecules that meet the pharmaceutical requirements for a given protein pocket
- Protein & Protein Pocket
  - Proteins perform a vast array of physiological functions
  - Pockets are the regions where proteins interact with drugs
- Pharmaceutical Requirement
  - Intra-molecule: drug-likeness, synthetic accessibility
  - Inter-molecule: strong binding affinity with proteins

- 1D/2D Drug Design
  - Represent molecules with 1D SMILES or 2D graph
  - Can not design the interaction in 3D space
  - Rely on bioactivity data to optimize molecules



From Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules

- 3D Drug Design
  - Supervised Method
    - Still need scarce experiment data



From A 3D Generative Model for Structure-Based Drug Design

- 3D Drug Design
  - Sampling Method
    - Use time-consuming docking simulation to provide supervised signals



From Knowledge Guided Geometric Editing for Unsupervised Drug Design

- Challenge
  - Reduce the dependence on experiment data
  - Design molecules more efficiently

## Motivation

- Massive data which are not from experiments
  - ZINC database has over 1000M predicted unbound molecules
- Molecular shape is stable when molecules bind to proteins
- Structure determines properties
  - Similar shape, similar properties
  - Complementary shape to the pocket, satisfactory binding affinity





## Motivation

- Idea
  - A shape-based molecule design model (pre-trained with massive unbound molecules) has the opportunity to generalize to the situation of designing bound molecules
  - Further, if we can obtain its input shape in a zero-shot way, the model can design drugs without experiment data and does not use the docking process to train itself

### DESERT

- Sketch some reasonable shapes complementary to the target pocket
- Generate 3D molecules with a pre-trained model to fill these shapes



## Sketching

- Ligand-based
  - Directly use the ligand's shape as the input
- Pocket-based
  - Pockets are much larger than ligands
  - Ligands lie in the area close to the pocket surface



## Sketching

- Pocket-based
  - Heuristically, we find a seed shape to intersect the pocket gradually
  - We get the seed shape by overlapping the shapes of several drug-like molecules
  - We stop the sketching process when the intersection has a similar size to a molecule



## Generating

- Shape2Mol
  - Encoder-Decoder architecture
  - Pre-train with massive unbound molecules



## Shape2Mol

- Shape Encoder
  - Input 3D images, i.e., voxelized molecular shapes
  - Extend ViT for 2D images to 3D images



## Shape2Mol

- 3D Molecule Decoder
  - Output the sequence of fragment tuples
    - Tokenization: turn a molecule graph into a tree structure object
    - Linearization: turn the tree into a fragment sequence
  - Modify the vanilla Transformer decoder for fragment sequences



 $T_i = (C_i, P_i, R_i)$  where  $C_i$  is the fragment category,  $P_i$  is the discreterized translation vector,  $R_i$  is the discreterized rotation vector

## Shape2Mol

• Training Loss

$$\mathcal{L} = -\sum_{i=1}^{n} \left\{ C_i \log \hat{C}_i + P_i^c \log \hat{P}_i^c + R_i^c \log \hat{R}_i^c \right\}$$

- Decoding Strategy
  - Nucleus sampling decoding strategy
  - Remove duplicate molecules
  - Leverage the docking process to drop results that do not pass the affinity threshold

## Experiment

- Baseline
  - 1D/2D: JT-VAE, MARS, etc.
  - 3D: liGAN, 3D SBDD, GEKO
  - Virtual Screening: SCREEN
- Dataset
  - 100M drug-like molecules from ZINC as training data
  - Following previous work, we test the method on 12 representative proteins
  - Only 2 of 12 have bioactivity data (Set B) and can be used to test 1D/2D methods
- Metrics
  - Each method provides 100 molecules for evaluation
  - Quality of designed molecular space: Uniq, Succ, Nov, Div, Prod
  - Ability of providing highly active molecules: Median (Median Vina Score)

Targets		Method	Uniq (%)↑	Succ (%)↑	Nov (%)↑	Div ↑	Prod ↑	Median (kcal/mol)↓
	Guided	GEKO [10]	100.0	55.7	100.0	0.912	0.51	-9.58
Set A	Supervised	liGAN [35] 3D SBDD [2]	100.0 69.7	0.4 13.6	100.0 98.9	0.924 0.839	0.00 0.08	-5.84 -8.83
	Retrieved	Screen (1K) Screen (200K)	100.0 100.0	25.6 64.0	100.0 100.0	0.892 0.889	0.23 <b>0.57</b>	-7.46 -8.66
	Ours	Desert-Ligand Desert-Pocket	100.0 100.0	65.3 61.1	87.0 100.0	0.786 0.908	0.41 <b>0.57</b>	-8.89 <b>-9.62</b>
Set B	Guided	JT-VAE [9] RationaleRL [23] GA + D [30] GraphAF [26] MolDQN [27] MolEvol [69] MARS [33] GEKO [10]	100.0 100.0 39.0 97.0 76.5 99.5 86.0 100.0	$\begin{array}{c} 13.0 \\ 27.0 \\ 24.0 \\ 0.5 \\ 0.0 \\ 40.5 \\ 31.5 \\ 57.0 \end{array}$	100.0 35.0 87.0 100.0 100.0 63.5 93.0 100.0	$\begin{array}{c} 0.907\\ 0.884\\ 0.852\\ 0.946\\ 0.742\\ 0.742\\ 0.805\\ 0.910\\ \end{array}$	$\begin{array}{c} 0.12 \\ 0.08 \\ 0.06 \\ 0.00 \\ 0.00 \\ 0.17 \\ 0.22 \\ 0.52 \end{array}$	-8.35 -7.75 -7.22 -4.22 -5.52 -8.19 -7.68 -9.19
	Supervised	liGAN [35] 3D SBDD [2]	99.8 99.9	0.2 5.2	100.0 100.0	0.923 0.853	0.00 0.05	-5.34 -6.39
	Retrieved	Screen (1K) Screen (200K)	100.0 100.0	3.0 32.0	100.0 100.0	0.891 0.882	0.03 0.28	-6.94 -7.95
	Ours	Desert-Ligand Desert-Pocket	100.0 100.0	18.0 61.0	100.0 100.0	0.913 0.907	0.17 <b>0.55</b>	-7.34 <b>-9.32</b>





Targets		Method	Uniq (%)↑	Succ (%)↑	Nov (%)↑	Div ↑	Prod ↑	Median (kcal/mol)↓
	Guided	GEKO [10]	100.0	55.7	100.0	0.912	0.51	-9.58
Set A	A Supervised Retrieved	liGAN [35] 3D SBDD [2]	100.0 69.7	0.4 13.6	100.0 98.9	0.924 0.839	$\begin{array}{c} 0.00\\ 0.08 \end{array}$	-5.84 -8.83
		Screen (1K) Screen (200K)	100.0 100.0	25.6 64.0	100.0 100.0	0.892 0.889	0.23 <b>0.57</b>	-7.46 -8.66
	Ours	Desert-Ligand Desert-Pocket	100.0 100.0	65.3 61.1	87.0 100.0	0.786 0.908	0.41 <b>0.57</b>	-8.89 <b>-9.62</b>
Set B	Guided	JT-VAE [9] RationaleRL [23] GA + D [30] GraphAF [26] MolDQN [27] MolEvol [69] MARS [33] GEKO [10]	100.0 100.0 39.0 97.0 76.5 99.5 86.0 100.0	$\begin{array}{c} 13.0\\ 27.0\\ 24.0\\ 0.5\\ 0.0\\ 40.5\\ 31.5\\ 57.0\\ \end{array}$	100.0 35.0 87.0 100.0 100.0 63.5 93.0 100.0	$\begin{array}{c} 0.907\\ 0.884\\ 0.852\\ 0.946\\ 0.742\\ 0.742\\ 0.805\\ 0.910\\ \end{array}$	$\begin{array}{c} 0.12 \\ 0.08 \\ 0.06 \\ 0.00 \\ 0.00 \\ 0.17 \\ 0.22 \\ 0.52 \end{array}$	-8.35 -7.75 -7.22 -4.22 -5.52 -8.19 -7.68 -9.19
	Supervised	liGAN [ <mark>35]</mark> 3D SBDD [2]	99.8 99.9	0.2 5.2	100.0 100.0	0.923 0.853	0.00 0.05	-5.34 -6.39
	Retrieved	Screen (1K) Screen (200K)	100.0 100.0	3.0 32.0	100.0 100.0	0.891 0.882	0.03 0.28	-6.94 -7.95
	Ours	Desert-Ligand Desert-Pocket	100.0 100.0	18.0 61.0	100.0 100.0	0.913 0.907	0.17 <b>0.55</b>	-7.34 <b>-9.32</b>



I. The zero-shot DESERT achieves the SOTA at fast speed

Targets	Method		Uniq (%)↑	Succ (%)↑	Nov (%)↑	Div ↑	Prod ↑	Median (kcal/mol)↓
	Guided	GEKO [10]	100.0	55.7	100.0	0.912	0.51	-9.58
Set A	Supervised	liGAN [35] 3D SBDD [2]	100.0 69.7	0.4 13.6	100.0 98.9	0.924 0.839	$\begin{array}{c} 0.00\\ 0.08 \end{array}$	-5.84 -8.83
	Retrieved	Screen (1K) Screen (200K)	100.0 100.0	25.6 64.0	100.0 100.0	0.892 0.889	0.23 <b>0.57</b>	-7.46 -8.66
	Ours	Desert-Ligand Desert-Pocket	100.0 100.0	65.3 61.1	87.0 100.0	0.786 0.908	0.41 <b>0.57</b>	-8.89 <b>-9.62</b>
Set B	Guided	JT-VAE [9] RationaleRL [23] GA + D [30] GraphAF [26] MolDQN [27] MolEvol [69] MARS [33] GEKO [10]	100.0 100.0 39.0 97.0 76.5 99.5 86.0 100.0	$\begin{array}{c} 13.0\\ 27.0\\ 24.0\\ 0.5\\ 0.0\\ 40.5\\ 31.5\\ 57.0\\ \end{array}$	100.0 35.0 87.0 100.0 100.0 63.5 93.0 100.0	$\begin{array}{c} 0.907\\ 0.884\\ 0.852\\ 0.946\\ 0.742\\ 0.742\\ 0.805\\ 0.910\\ \end{array}$	$\begin{array}{c} 0.12 \\ 0.08 \\ 0.06 \\ 0.00 \\ 0.00 \\ 0.17 \\ 0.22 \\ 0.52 \end{array}$	-8.35 -7.75 -7.22 -4.22 -5.52 -8.19 -7.68 -9.19
	Supervised	liGAN [ <mark>35]</mark> 3D SBDD [2]	99.8 99.9	0.2 5.2	100.0 100.0	0.923 0.853	$\begin{array}{c} 0.00\\ 0.05 \end{array}$	-5.34 -6.39
	Retrieved	Screen (1K) Screen (200K)	100.0 100.0	3.0 32.0	100.0 100.0	0.891 0.882	0.03 0.28	-6.94 -7.95
	Ours	Desert-Ligand Desert-Pocket	$\begin{array}{c} 100.0\\ 100.0 \end{array}$	18.0 61.0	100.0 100.0	0.913 0.907	0.17 <b>0.55</b>	-7.34 <b>-9.32</b>



I. The zero-shot DESERT achieves the SOTA at fast speedII. The shape helps DESERT produce high quality molecules

Targets	Method		Uniq (%)↑	Succ (%)↑	Nov (%)↑	Div ↑	Prod ↑	Median (kcal/mol)↓
	Guided	GEKO [10]	100.0	55.7	100.0	0.912	0.51	-9.58
Set A	Supervised	liGAN [35] 3D SBDD [2]	100.0 69.7	0.4 13.6	100.0 98.9	0.924 0.839	$\begin{array}{c} 0.00\\ 0.08 \end{array}$	-5.84 -8.83
	Retrieved	Screen (1K) Screen (200K)	100.0 100.0	25.6 64.0	100.0 100.0	0.892 0.889	0.23 <b>0.57</b>	-7.46 -8.66
	Ours	Desert-Ligand	100.0	65.3	87.0	0.786	0.41	-8.89
	Ours	Desert-Pocket	100.0	61.1	100.0	0.908	0.57	-9.62
Set B	Guided	JT-VAE [9] RationaleRL [23] GA + D [30] GraphAF [26] MolDQN [27] MolEvol [69] MARS [33] GEKO [10]	100.0 100.0 39.0 97.0 76.5 99.5 86.0 100.0	$\begin{array}{c} 13.0 \\ 27.0 \\ 24.0 \\ 0.5 \\ 0.0 \\ 40.5 \\ 31.5 \\ 57.0 \end{array}$	100.0 35.0 87.0 100.0 63.5 93.0 100.0	$\begin{array}{c} 0.907\\ 0.884\\ 0.852\\ 0.946\\ 0.742\\ 0.742\\ 0.805\\ 0.910\\ \end{array}$	$\begin{array}{c} 0.12 \\ 0.08 \\ 0.06 \\ 0.00 \\ 0.00 \\ 0.17 \\ 0.22 \\ 0.52 \end{array}$	-8.35 -7.75 -7.22 -4.22 -5.52 -8.19 -7.68 -9.19
	Supervised	liGAN [ <mark>35</mark> ] 3D SBDD [2]	99.8 99.9	0.2 5.2	$\begin{array}{c} 100.0\\ 100.0 \end{array}$	0.923 0.853	$\begin{array}{c} 0.00\\ 0.05 \end{array}$	-5.34 -6.39
	Retrieved	Screen (1K) Screen (200K)	100.0 100.0	3.0 32.0	100.0 100.0	0.891 0.882	0.03 0.28	-6.94 -7.95
	Ours	DESERT-LIGAND DESERT-POCKET	100.0 100.0	18.0 61.0	100.0 100.0	0.913 0.907	0.17 <b>0.55</b>	-7.34 <b>-9.32</b>



I. The zero-shot DESERT achieves the SOTA at fast speed
II. The shape helps DESERT produce high quality molecules
III. More comprehensive exploration of protein pockets benefits performance

Targets	Method		Uniq (%)↑	Succ (%)↑	Nov (%)↑	Div ↑	Prod ↑	Median (kcal/mol)↓
	Guided	GEKO [10]	100.0	55.7	100.0	0.912	0.51	-9.58
Set A	Supervised	liGAN [35] 3D SBDD [2]	100.0 69.7	0.4 13.6	100.0 98.9	0.924 0.839	$\begin{array}{c} 0.00\\ 0.08 \end{array}$	-5.84 -8.83
	Retrieved	Screen (1K) Screen (200K)	100.0 100.0	25.6 64.0	100.0 100.0	0.892 0.889	0.23 <b>0.57</b>	-7.46 -8.66
	Ours	Desert-Ligand Desert-Pocket	100.0 100.0	65.3 61.1	87.0 100.0	0.786 0.908	0.41 <b>0.57</b>	-8.89 <b>-9.62</b>
Set B	Guided	JI-VAE [9] RationaleRL [23] GA + D [30] GraphAF [26] MolDQN [27] MolEvol [69] MARS [33] GEKO [10]	100.0 100.0 39.0 97.0 76.5 99.5 86.0 100.0	$ \begin{array}{r} 13.0\\27.0\\24.0\\0.5\\0.0\\40.5\\31.5\\57.0\end{array} $	100.0 35.0 87.0 100.0 100.0 63.5 93.0 100.0	$\begin{array}{c} 0.907 \\ 0.884 \\ 0.852 \\ 0.946 \\ 0.742 \\ 0.742 \\ 0.805 \\ 0.910 \end{array}$	$\begin{array}{c} 0.12 \\ 0.08 \\ 0.06 \\ 0.00 \\ 0.00 \\ 0.17 \\ 0.22 \\ 0.52 \end{array}$	-8.35 -7.75 -7.22 -4.22 -5.52 -8.19 -7.68 -9.19
	Supervised	liGAN [35] 3D SBDD [2]	99.8 99.9	0.2 5.2	100.0 100.0	0.923 0.853	$0.00 \\ 0.05$	-5.34 -6.39
	Retrieved	Screen (1K) Screen (200K)	100.0 100.0	3.0 32.0	100.0 100.0	0.891 0.882	0.03 0.28	-6.94 -7.95
	Ours	Desert-Ligand Desert-Pocket	100.0 100.0	18.0 61.0	100.0 100.0	0.913 0.907	0.17 <b>0.55</b>	-7.34 <b>-9.32</b>



- I. The zero-shot DESERT achieves the SOTA at fast speed
- *II.* The shape helps DESERT produce high quality molecules
- *III. More comprehensive exploration of protein pockets benefits performance*
- *IV.* Unsupervised methods have larger potential than the supervised counterparts

## Shape Faithfulness & Structure Rationality

Method	Shape Tanimoto	Free Energy (kcal/mol)
Random	0.325	/
Real	/	167.28
liGAN (Ligand)	0.869	289.55
DESERT-LIGAND	0.875	188.54



## Shape Faithfulness & Structure Rationality

Method	Shape Tanimoto	Free Energy (kcal/mol)
Random	0.325	/ 167.28
liGAN (Ligand) DESERT-LIGAND	0.869 0.875	289.55 188.54

*I.* DESERT can design molecules that fit shapes



## Shape Faithfulness & Structure Rationality

Method	Shape Tanimoto	Free Energy (kcal/mol)
Random	0.325	167.29
liGAN (Ligand)	0.869	289.55
DESERT-LIGAND	0.875	188.54



- *I.* DESERT can design molecules that fit shapes
- *II.* Fragments make DESERT's results have more correct molecular structures

## Ablation Study (Generating)

#### 0.956 0.959 0.955 category accuarcy 0.929 0.918 translation accuarcy 0.769 0.763 0.771 0.748 0.539 0.677 0.678 0.680 rotation accuracy 0.583 0.372 0.874 0.873 0.875 shape animoto 0.859 0.824 0.5M 4.5M 4.5M(base) 50M 100M

Pre-training Configuration

- I. Larger model achieves better performance
- *II. Performance saturation occurs when the dataset is of moderate size*

#### Robust Training & Discretization



#### **Decoding Strategy**

Sampling Method	Div	Prod	Median
Beam Search (Beam=10)	0.70	0.00	-5.87
Greedy Decoding	0.65	0.00	-5.83
Top K (K=10)	0.91	0.04	-5.99
Top P (P=0.95)	0.93	0.06	-6.01
+ post-processing	0.92	0.17	-7.34

- I. Model trained with shape noise shows better performance when test data are noisy
- *II.* Discretization consistently improves the result
- *I.* Beam Search and Greedy Decoding are poor at providing diverse molecules
- *II.* Top K and Top P can provide relatively diverse results

## Ablation Study (Sketching)

Sampling Space Size



Seed Shape Type

Seed Shape	Succ	Prod	Median
None	82.0	0.74	-8.85
Sphere	75.5	0.68	-9.13
Molecules	61.0	0.55	-9.32

- *I. Increasing sampling space size leads to better performance*
- *II.* The shape can effectively prune the sampling space for screening

*I.* Directly using the pocket as the shape may contribute to a suboptimal result

## Chemical Information

Method	Prod	Median
DESERT-POCKET	0.55	-9.32
+ chemical(Weak)	0.53	-9.19
+ chemical(Strong)	0.52	-9.03

*I.* DESERT does not achieve better performance when we increase the effect of chemical information

## Conclusion

- We propose a zero-shot drug design method DESERT
- DESERT utilizes a large-scale molecular database to reduce the dependence on experimental data and docking simulation
- Experiments show that DESERT achieves a new state-of-the-art at a fast speed